Skip to content
Clinical Trials – home

Hopital Des Enfants

Research site

France 330 Avenue De Grande Bretagne, 31059 Toulouse, France

  • 20 trials recruiting
  • Neuroblastoma · Obesity · Spinal muscular atrophy
  • Adults and children

About Specializations

Hopital Des Enfants in Toulouse, France specialises in clinical trials of conditions such as Neuroblastoma, Obesity, Spinal muscular atrophy, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematology

The medical center is at the forefront of pediatric oncology and hematology, focusing on innovative treatments for challenging conditions such as acute myeloid leukemia and neuroblastoma. Through clinical trials, the center explores the efficacy of novel drug combinations and targeted therapies to improve survival rates and quality of life for young patients.

  • Acute Myeloid Leukemia (AML)
  • High-Risk Neuroblastoma
  • Recurrent and Primary Refractory Ewing Sarcoma

By integrating cutting-edge research with clinical practice, the center aims to set new standards in the treatment of pediatric cancers.

Neurology

Specializing in pediatric neurology, the center conducts extensive research on conditions like spinal muscular atrophy and epilepsy. The focus is on developing therapies that enhance neurological function and improve patient outcomes through innovative pharmacological approaches.

  • Spinal Muscular Atrophy (SMA)
  • Childhood Epilepsy
  • Migraine Prevention

The center's commitment to neurological research is evident in its pursuit of therapies that address both the symptoms and underlying causes of these complex disorders.

Immunology and Autoimmune Diseases

Focusing on immunology and autoimmune diseases, the center is dedicated to advancing treatments for conditions such as systemic lupus erythematosus and juvenile psoriatic arthritis. Research efforts aim to refine therapeutic strategies that modulate the immune system to achieve better disease control.

  • Systemic Lupus Erythematosus (SLE)
  • Juvenile Psoriatic Arthritis
  • Childhood Idiopathic Nephrotic Syndrome

Through innovative clinical trials, the center seeks to enhance the efficacy and safety of treatments for pediatric autoimmune conditions.

Gastroenterology

The center is a leader in pediatric gastroenterology, with a focus on inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Research initiatives aim to develop therapies that offer improved symptom management and long-term remission.

  • Ulcerative Colitis
  • Crohn's Disease

By exploring novel pharmacological agents, the center strives to provide comprehensive care that addresses both the physical and emotional needs of young patients.

Endocrinology and Growth Disorders

In the field of endocrinology, the center focuses on growth disorders such as achondroplasia and short stature conditions. Research is directed towards optimizing growth outcomes through innovative hormonal therapies and genetic interventions.

  • Achondroplasia
  • Short Stature Disorders

The center's research efforts are dedicated to improving the quality of life for children with growth disorders by advancing therapeutic options.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
330 Avenue De Grande Bretagne31059 ToulouseFrance
Recruiting now
20 trials
Conditions studied
46

More sites in ToulouseFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

48 clinical trials

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Indacaterol Acetate
  • Sponsor:Novartis Pharma AG

A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Sponsor:Merck Sharp & Dohme LLC

Long-Term Study of Vosoritide Safety and Effectiveness in Children with Hypochondroplasia Until Adult Height is Reached

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Vosoritide
  • Sponsor:Biomarin Pharmaceutical Inc.

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Short stature

Recruiting

Study on the Effects of Vosoritide for Children with Idiopathic Short Stature

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Vosoritide
  • Sponsor:Biomarin Pharmaceutical Inc.

Study on the Safety and Effectiveness of Bexicaserin for Seizures in Children and Adults with Developmental and Epileptic Encephalopathy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Alagille syndrome+1

Recruiting

Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Maralixibat
  • Sponsor:Mirum Pharmaceuticals Inc.

Study on the Effects of Pitolisant Hydrochloride for Patients with Prader-Willi Syndrome

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pitolisant hydrochloride
  • Sponsor:Harmony Biosciences LLC

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:The University Of Birmingham

Migraine

Recruiting

Study on Rimegepant for Preventing Migraines in Children and Teens Aged 6 to 17

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.